<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> alpha-amino-3-hydroxy 5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-<z:chebi fb="0" ids="35595">isoxazole</z:chebi> <z:chebi fb="0" ids="17272">propionate</z:chebi> (AMPA) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> LY-293558 in reducing ischemic brain damage have been assessed in <z:chebi fb="2" ids="5615">halothane</z:chebi>-anesthetized cats </plain></SENT>
<SENT sid="1" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was produced by permanent occlusion of one middle cerebral artery, and the animals were killed 6 h later </plain></SENT>
<SENT sid="2" pm="."><plain>The amount of early irreversible ischemic damage was assessed at 16 predetermined stereotactic planes by an observer blinded to treatment paradigm employed </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with LY-293558 (15 mg/kg i.v., plus infusion of 7 mg/kg/h) initiated 30 min prior to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> reduced significantly (p &lt; 0.02) the volume of ischemic damage (from 3,423 +/- 212 mm3 of the cerebral hemisphere in vehicle-treated cats to 2,822 +/- 569 mm3 in LY-293558-treated cats) </plain></SENT>
<SENT sid="4" pm="."><plain>The present data demonstrate that an AMPA receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> can reduce focal ischemic damage in a gyrencephalic species in which key physiological variables have been controlled and monitored throughout the postischemic period </plain></SENT>
<SENT sid="5" pm="."><plain>These data provide additional support for the clinical evaluation of AMPA receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> in focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in humans </plain></SENT>
</text></document>